AEON Biopharma, Inc. (AEON) shareholders
Close on Nov 16, 2026Market cap $7.02MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Daewoong Co., Ltd. Joint filing with Daewoong Pharmaceutical Co., Ltd. (30.50%) | 23,242,546 | 30.60% | 13D (active) amendment | Oct 30, 2026 |
| Daewoong Pharmaceutical Co. Ltd ("DWP") Joint filing with Daewoong Co.,Ltd. ("DWC") (49.99%) | 12,009,737 | 49.75% | 13D (active) | Jan 21, 2026 |
| Stonepine GP, LLC Joint filing with Stonepine Capital Management, LLC (9.90%), Stonepine Capital, L.P. (9.90%) and 1 more | 6,892,682 | 9.90% | 13G (passive) | Jul 15, 2026 |
| Timothy P. Lynch | 6,500,000 | 13.00% | 13G (passive) | Aug 19, 2026 |
| Bigger Michael | 4,900,000 | 6.10% | 13G (passive) | Jan 6, 2025 |
| Robert J Palmisano Joint filing with The Palmisano Family, LLC (5.70%) | 2,265,000 | 5.70% | 13D (active) amendment | Jul 25, 2024 |
| The Palmisano Family, LLC Joint filing with Robert J Palmisano (5.70%) | 2,265,000 | 5.70% | 13D (active) | Jul 25, 2024 |
| Chernett Jorey | 1,128,500 | 9.90% | 13G (passive) | May 27, 2025 |
| Dauntless Investment Group, LLC | 108,224 | 9.70% | 13G (passive) | Feb 26, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AEON | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Dauntless Investment Group, LLC | 12,490,154 | 25.04% | $8.98M | +9,962,379 | 7.06% |
| Geode Capital Management, LLC | 95,311 | 0.19% | $68.56K | +8,249 | 0.00% |
| Vanguard Capital Management LLC | 90,529 | 0.18% | $65.09K | – | 0.00% |
| Blue Owl Capital Holdings LP | 42,353 | 0.08% | $30.49K | – | 0.00% |
| Formidable Asset Management, LLC | 20,024 | 0.04% | $19.72K | – | 0.00% |
| StoneX Group Inc. | 18,953 | 0.04% | $14.94K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 13,713 | 0.03% | $9.86K | −989 | 0.00% |
| LPL Financial LLC | 11,507 | 0.02% | $8.28K | – | 0.00% |
| Citigroup Inc | 7,315 | 0.01% | $5.26K | +6,573 | 0.00% |
| UBS Group AG | 5,062 | 0.01% | $3.64K | +880 | 0.00% |
| BlackRock, Inc. | 2,834 | 0.01% | $2.04K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 2,567 | 0.01% | $1.85K | +2,097 | 0.00% |
| Steward Partners Investment Advisory, LLC | 1,100 | 0.00% | $791 | – | 0.00% |
| Wolff Wiese Magana LLC | 567 | 0.00% | $408 | – | 0.00% |
| SBI Securities Co., Ltd. | 232 | 0.00% | $167 | +127 | 0.00% |
| Dupont Capital Management Corp | 170 | 0.00% | $122 | – | 0.01% |
| Morgan Stanley | 150 | 0.00% | $108 | – | 0.00% |
| GHP Investment Advisors, Inc. | 95 | 0.00% | $69 | – | 0.00% |
| Wells Fargo & Company/Mn | 90 | 0.00% | $65 | – | 0.00% |
| Barclays PLC | 59 | 0.00% | $42 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 22 | 13M | 25.7% | 2 / 6 | 1 / 4 | 10M | 0M |
| Q1 2026 | 24 | 3M | 5.7% | 9 / 4 | 2 / 5 | 1M | 0M |
| Q4 2025 | 22 | 2M | 4.9% | 4 / 8 | 1 / 3 | 1M | 0M |
| Q3 2025 | 21 | 1M | 2.7% | 5 / 2 | 3 / 2 | 0M | 0M |
| Q2 2025 | 18 | 1M | 2.5% | 3 / 4 | 1 / 1 | 0M | 0M |
| Q1 2025 | 16 | 2M | 3.1% | 3 / 4 | 6 / 24 | 1M | 0M |
| Q4 2024 | 37 | 0M | 0.2% | 8 / 8 | 10 / 1 | 0M | 0M |
| Q3 2024 | 30 | 0M | 0.3% | 14 / 5 | 3 / 7 | 0M | 0M |
| Q2 2024 | 25 | 0M | 0.3% | 3 / 10 | 7 / 5 | 0M | 0M |
| Q1 2024 | 27 | 0M | 0.3% | 8 / 10 | 3 / 1 | 0M | 0M |
| Q4 2023 | 20 | 0M | 0.2% | 6 / 4 | 3 / 1 | 0M | 0M |
| Q3 2023 | 15 | 0M | 0.1% | 15 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
4 funds held AEON in Q2 2026, 59% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of AEON | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 90,529 | 0.18% | $65.12K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 47,535 | 0.10% | $35.97K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 11,192 | 0.02% | $8.47K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 3,072 | 0.01% | $2.32K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Robert E. Bancroft | PRESIDENT & CEO, Director | 3,177,103 | 6.37% | Feb 19, 2026 |
| John Bencich | CHIEF FINANCIAL OFFICER | 754,717 | 1.51% | Apr 3, 2026 |
| Chad Oh | CHIEF MEDICAL OFFICER | 2,183,436 | 4.38% | Mar 11, 2026 |
| Alexander Blair Wilson | CLO, CSO, and Corp Secretary | 2,183,005 | 4.38% | Mar 5, 2026 |
| Jennifer Sy | PRINCIPAL ACCOUNTING OFFICER | 1,501,176 | 3.01% | Mar 5, 2026 |
| Robert J. Palmisano | Director | 2,523,705 | 5.06% | Jun 22, 2026 |
| Marc Forth | Director | 973,231 | 1.95% | Jun 22, 2026 |
| Shelley B. Thunen | Director | 258,705 | 0.52% | Jun 22, 2026 |
| Jost Fischer | Director | 489,469 | 0.98% | Jun 22, 2026 |
| Eric G. Carter | Director | 258,705 | 0.52% | Jun 22, 2026 |
| Daewoong Co., Ltd | 10% owner | 35,252,283 | 70.67% | Nov 10, 2026 |
| Timothy P. Lynch | 10% owner | 6,500,000 | 13.03% | Aug 21, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Daewoong Co., Ltd 10% owner | Oct 30, 2026 | Other | −3,822 | $0.29 | $1.12K | 23,184,523 |
| Daewoong Co., Ltd 10% owner | Oct 30, 2026 | Option exercise | +11,236,631 | $0.00 | $1.12K | 23,188,345 |
| Timothy P. Lynch 10% owner | Aug 19, 2026 | Buy | +1,150,000 | $0.21 | $241.50K | 6,500,000 |
| Shelley B. Thunen Director | Jun 17, 2026 | Award | +222,684 | – | – | 258,705 |
| Eric G. Carter Director | Jun 17, 2026 | Award | +222,684 | – | – | 258,705 |
| Jost Fischer Director | Jun 17, 2026 | Award | +222,684 | – | – | 489,469 |
| Marc Forth Director | Jun 17, 2026 | Award | +222,684 | – | – | 973,231 |
| Robert J. Palmisano Director | Jun 17, 2026 | Award | +222,684 | – | – | 258,705 |
| John Bencich CHIEF FINANCIAL OFFICER | Apr 2, 2026 | Award | +754,717 | – | – | 754,717 |
| Chad Oh CHIEF MEDICAL OFFICER | Mar 4, 2026 | Award | +1,316,872 | – | – | 2,183,436 |
| Jennifer Sy PRINCIPAL ACCOUNTING OFFICER | Mar 4, 2026 | Award | +925,925 | – | – | 1,501,176 |
| Alexander Blair Wilson CLO, CSO, and Corp Secretary | Mar 4, 2026 | Award | +1,316,872 | – | – | 2,183,005 |
| Chad Oh CHIEF MEDICAL OFFICER | Feb 17, 2026 | Award | +862,500 | – | – | 866,564 |
| Jennifer Sy PRINCIPAL ACCOUNTING OFFICER | Feb 17, 2026 | Award | +575,000 | – | – | 575,251 |
| Alexander Blair Wilson CLO, CSO, and Corp Secretary | Feb 17, 2026 | Award | +862,500 | – | – | 866,133 |
| Robert E. Bancroft PRESIDENT & CEO, Director | Feb 17, 2026 | Award | +3,000,000 | – | – | 3,177,103 |
| Jost Fischer Director | May 21, 2025 | Buy | +60,000 | $0.49 | $29.40K | 266,785 |
| Jost Fischer Director | May 20, 2025 | Buy | +60,000 | $0.51 | $30.60K | 206,785 |
| Jost Fischer Director | May 19, 2025 | Buy | +50,000 | $0.50 | $25.00K | 146,785 |
| Robert E. Bancroft President & CEO, Director | May 14, 2025 | Award | +177,103 | – | – | 177,103 |
| Robert J. Palmisano Director | Aug 31, 2024 | Award | +36,021 | – | – | 36,021 |
| Robert J. Palmisano Director | Aug 31, 2024 | Award | +36,021 | – | – | 36,021 |
| Marc Forth CHIEF EXECTUIVE OFFICER, Director | Aug 31, 2024 | Award | +470,692 | – | – | 750,547 |
| Jost Fischer Director | Aug 31, 2024 | Award | +36,021 | – | – | 96,785 |
| Alexander Blair Wilson EXEC VP, CLO & CORP SECRETARY | Aug 31, 2024 | Award | +180,110 | – | – | 261,538 |
| Shelley B. Thunen Director | Aug 31, 2024 | Award | +36,021 | – | – | 36,021 |
| Jennifer Sy PRINCIPAL ACCOUNTING OFFICER | Aug 31, 2024 | Award | +18,010 | – | – | 18,010 |
| Eric G. Carter Director | Aug 31, 2024 | Award | +36,021 | – | – | 36,021 |
| Chad Oh CHIEF MEDICAL OFFICER | Aug 31, 2024 | Award | +192,117 | – | – | 292,545 |
| Strathspey Crown Holdings Group, LLC 10% owner | Aug 11, 2023 | Sale | −7,380,394 | $10.00 | $73.80M | 2,031,773 |
| Oleg Grodnensky 10% owner | Jul 21, 2023 | Conversion | +89,163 | – | – | 6,989,163 |
| Oleg Grodnensky 10% owner | Jul 21, 2023 | Conversion | +6,900,000 | – | – | 6,900,000 |
| Jost Fischer Director | Jul 21, 2023 | Award | +2,353 | – | – | 2,353 |
| Jost Fischer Director | Jul 21, 2023 | Award | +13,274 | – | – | 13,274 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of AEON Biopharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 435,695 shares on Sep 11, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Oleg Grodnensky Affiliate | Jul 29, 2024 | 201,825 | $530.78K | Jul 29, 2024 | Exercise of Warrants 03/29/2024 |
See a number that looks wrong?